Pharmaceutical companies Merck and ALk have produced a daily pill made from dust mites. The pill is officially known as “sublingual immunotherapy”.
Sublingual immunotherapy is homeopathy:
The major principle of homeopathy is “Like cures Like”, i.e.: dust mite to cure dust mite;
Homeopathy is taken sublingually, rather than through the digestive system typical of conventional medicine;
Homeopathy acts on the immune system which is active in the process of recovery to a balanced state of health.
In plain English: The pharmaceuticals are manufacturing homeopathic medicine.
Oliver Moody Science Correspondent
Published at 12:01AM, November 11 2015
Millions of Britons who suffer from dust allergies could be offered a lasting cure within a year after successful trials of a pill made from mites.The daily tablet, which builds up the body’s tolerance over several months, would supersede injections and could also relieve the symptoms of asthma.As many as 12 million Britons are thought to struggle with ailments brought on by dust mites, with symptoms including wheezing, disturbed sleep and inflammation.At present, several sufferers are offered jabs to boost their immune systems against the allergy. Most have to make do with antihistamines that offer temporary relief.A pill consisting of freeze-dried dust mites that dissolves under the tongue could prove to be a cheap alternative, a growing body of scientific evidence suggests.The treatment has been approved by the European drugs watchdog and experts believe it could appear in British pharmacies next year.The pill, officially known as house dust mite sublingual immunotherapy, has been developed by the pharmaceutical companies Merck and ALK.It acts like a vaccine, gradually making the immune system accustomed to dust mites. It begins to ease the symptoms within three to four months, according to a clinical trial released this year that involved almost 1,000 European adults.The results from another trial, published last weekend in the Annals of Allergy, Asthma and Immunology, appear to show that it is safe for most teenagers, although many had minor irritation in their mouths and eyes. Two patients had life-threatening allergic reactions.Other tests indicate that it could be a potent treatment for asthma, which affects 5.4 million people in Britain and is often closely linked to dust. The tablet seems to be a particularly effective treatment for those whose asthma cannot be controlled with inhalers.Hendrik Nolte, a scientist at Merck who has played a leading role in developing the drug, said one study had shownn that it cut the number of asthma attacks by a third.The pill won approval from the European Medicines Agency in August and will soon go on sale in 11 countries including France, Germany and Italy.Sofia Grigoriadou, clinical secretary of the British Society for Immunology and a consultant immunologist at Barts Health NHS trust in London, said she expected British regulators to follow suit.“It’s definitely something that’s going to be coming forward,” she said. “This [latest] paper is a safety trial but there’s good evidence that this treatment is working for adults, it’s improving the symptoms of rhinitis [inflammation in the nose] and as a consequence works for asthma.”Dr Grigoriadou said the side effects, including swelling of the throat and mouth and itchy eyes, experienced by many patients during the first fortnight of the treatment, was a downside. For the significant minority whose quality of life was seriously spoiled by their allergy, however, the tablet provided a major improvement, she added.